Drug Trial Radar · NCT05327530
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)
Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
256
Actual
Start
Aug 17, 2022
Primary completion
Jun 20, 2025
Study completion Jan 22, 2027
Sponsor
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics
- First posted
- Apr 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and efficacy of avelumab in combination with other anti-tumor agents as a maintenance treatment in participants with bladder cancer.
Conditions
- Locally Advanced or Metastatic Urothelial Carcinoma
Interventions
AvelumabDrug
Participants received intravenous infusion of Avelumab at a dose of 800 mg once every 2 weeks until unacceptable toxicity, withdraw consent or initiation of a new treatment.
Sacituzumab Govitecan (SG)Drug
Participants received intravenous infusion SG at dose of 10 mg/kg of bodyweight once a week on Day 1 and 8 of each 21-daytreatment cycles until unacceptable toxicity, withdraw consent or initiation of a new treatment.
M6223Drug
Participants intravenous infusion of M6223 at dose of 1600 mg once every 2 weeks until unacceptable toxicity, withdraw consent or initiation of a new treatment.
NKTR-255Drug
Participants intravenous infusion of NKTR-255 at a dose of 3 mcg/kg of body weight once every 4 weeks until unacceptable toxicity, withdraw consent or initiation of a new treatment.
JB100Drug
As per the Clinical Study Protocol, the control group (avelumab alone) was extended by data from an external control, i.e. the JAVELIN Bladder 100 study (JB100) (NCT02603432). Participants received an intravenous infusion of 10 mg/kg of Avelumab along with best supportive care (BSC), on Day 1 and 15 of each 28 days treatment cycle, until confirmed disease progression, participant refusal, lost to follow up, unacceptable toxicity, or study termination by the sponsor, whichever occurred first. BSC was administered asper the treating physician. Participants were followed up until death, end of the study or withdrawal of consent, whichever comes first, regardless of initiation of new anticancer therapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by Investigator - Avelumab + Sacituzumab Govitecan Versus Avelumab Monotherapy (Avelumab [Control Group] + JB 100 [External Control])Time frame: Time from date of randomization to first documentation of progressive disease (PD) or death, assessed up to 32 months and 12 days (current study) and 41 months (JB100 extended control group)
- Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by Investigator - Avelumab + M6223 Versus Avelumab Monotherapy (Avelumab [Control Group] + JB 100 [External Control])Time frame: Time from date of randomization to first documentation of progressive disease (PD) or death, assessed up to 32 months and 12 days (current study) and 41 months (JB100 extended control group)
- Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by Investigator - Avelumab + NKTR-255 Versus Avelumab Monotherapy (Avelumab [Control Group] + JB 100 [External Control])Time frame: Time from date of randomization to first documentation of progressive disease (PD) or death, assessed up to 32 months and 12 days (current study) and 41 months (JB100 extended control group)
- Number of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment-Related Adverse Events, and AEs of Special Interest (AESIs)Time frame: Up to 32 months and 12 days (Current study) and 61 months and 11 days (JB100 extended control group)
Locations
98 sites in 12 countries. Site status is shown where the registry gives one.
Beacon Cancer Care
Coeur d'Alene, Idaho
University of Kansas Medical Center Research Institute, Inc. - 3901 Rainbow (MAIN)
Kansas City, Kansas
Johns Hopkins University
Baltimore, Maryland
The Johns Hopkins Hospital
Baltimore, Maryland
AMR Kansas City, Formerly Center for Pharmaceutical Research, an AMR company - Kansas City, MO at St. Joseph Medical Center
Kansas City, Missouri
Seattle Cancer Care Alliance
Seattle, Washington
Multicare Health System Tacoma General Hospital
Tacoma, Washington
University of Wisconsin Cancer Center
Madison, Wisconsin
Flinders Medical Centre
Bedford Park, Australia
Sunshine Hospital - PARENT
Footscray, Australia
Ashford Cancer Centre Research
Kurralta Park, Australia
Liverpool Hospital - PARENT
Liverpool, Australia
Calvary Mater Newcastle - PARENT
Newcastle, Australia
Tasman Oncology Research Ltd - Oncology
Southport, Australia
Macquarie University Hospital - PARENT
Sydney, Australia
The Kinghorn Can Cen
Westmead, Australia
ZNA Middelheim - Middelheim - account 2
Antwerp, Belgium
AZ Klina - PARENT
Brasschaat, Belgium
Institut Jules Bordet - Medical Oncology
Brussels, Belgium
Universitair Ziekenhuis Gent - Medical Oncology
Ghent, Belgium
AZ Groeninge - Campus Kennedylaan - account 2
Kortrijk, Belgium
Centre Hospitalier de l'Ardenne - PARENT
Libramont, Belgium
CHU de Liège - PARENT
Liège, Belgium
Universitaetsklinikum Wuerzburg - Klinik u. Poliklinik f. Urologie u. Kinderurologie
Wuerzburg, Belgium
William Osler Health System - Brampton Civic Hospital
Brampton, Canada
CISSS de la Monteregie-Centre - Hospital Charles Le Moyne
Greenfield Park, Canada
CHUM Centre de Recherche
Montreal, Canada
The Ottawa Hospital Cancer Centre
Ottawa, Canada
ICO - Site Paul Papin - service d'oncologie medicale
Angers, France
Institut Bergonié - Service d'Oncologie Médicale
Bordeaux, France
Centre François Baclesse - Pathologies Gynecologiques
Caen, France
Hôpital Henri Mondor - Service d'Oncologie Médicale
Créteil, France
Clinique Victor Hugo - Centre Jean Bernard - Service d'Oncologie Médical
Le Mans, France
Centre Leon Berard - Service d'Oncologie Medicale
Lyon, France
Hôpital de la Timone - service d'urologie
Marseille, France
Hopital Caremeau - Service Hématologie Clinique/Oncologie Médicale
Nîmes, France
Hôpital Cochin - Hematologie et Oncologie Médicale
Paris, France
CHU Poitiers - Hôpital la Milétrie - service d'oncologie médicale
Poitiers, France
CRLCC Eugene Marquis - Service d'Oncologie médicale
Rennes, France
ICO - Site René Gauducheau - Service d'Oncologie medicale
Saint-Herblain, France
Showing 40 of 98 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.